Cargando…

Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes

Glucagonlike peptide 1 (GLP-1) receptor agonists have been efficacious for the treatment of type 2 diabetes due to their ability to reduce weight and attenuate hyperglycemia. However, the activity of glucagonlike peptide 1 receptor–directed strategies is submaximal, and the only potent, sustainable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Capozzi, Megan E, DiMarchi, Richard D, Tschöp, Matthias H, Finan, Brian, Campbell, Jonathan E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2018
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263842/ https://www.ncbi.nlm.nih.gov/pubmed/29905825 http://dx.doi.org/10.1210/er.2018-00117

Ejemplares similares

Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes
por: Finan, Brian, et al.
Publicado: (2020)

Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
por: Jall, Sigrid, et al.
Publicado: (2017)

GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017)

Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
por: Tan, Qiming, et al.
Publicado: (2022)

Potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes
por: Araki, Eiichi, et al.
Publicado: (2022)

Pharmacological antagonism of the incretin system protects against diet-induced obesity
por: Svendsen, Berit, et al.
Publicado: (2019)

OR28-5 Bile Acid Sequestration Accelerates Glucagon Receptor-Mediated Body Weight Loss in Obese Mice
por: Kim, Teayoun, et al.
Publicado: (2019)

Outstanding Scientific Achievement Award Lecture 2011: Defeating Diabesity: The Case for Personalized Combinatorial Therapies
por: Tschöp, Matthias H., et al.
Publicado: (2012)

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
por: Mroz, Piotr A., et al.
Publicado: (2018)

SAT-655 Bile Acid Sequestration Synergistically Accelerates Glucagon Receptor-Stimulated Body Weight Loss in Diet-Induced Obese Mice
por: Kim, Teayoun, et al.
Publicado: (2020)

A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia()
por: Chabenne, Joseph, et al.
Publicado: (2014)

GLP-1–oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice
por: Schwenk, Robert W., et al.
Publicado: (2014)

The incretin/glucagon system as a target for pharmacotherapy of obesity
por: Del Prato, Stefano, et al.
Publicado: (2021)

Anti-obesity drug discovery: advances and challenges
por: Müller, Timo D., et al.
Publicado: (2021)

Hypothalamic Glucagon Receptors Regulate Feeding in Mice
por: Cunningham, Stephen E, et al.
Publicado: (2021)

Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis
por: Tiano, Joseph P., et al.
Publicado: (2015)

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
por: Knerr, Patrick J., et al.
Publicado: (2022)

Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety
por: He, Rongjun, et al.
Publicado: (2019)

GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease
por: Sachs, Stephan, et al.
Publicado: (2023)

Glucagon receptor signaling regulates weight loss via central KLB receptor complexes
por: Nason, Shelly R., et al.
Publicado: (2021)

Linked Toll-Like Receptor Triagonists Stimulate Distinct, Combination-Dependent Innate Immune Responses
por: Albin, Tyler J., et al.
Publicado: (2019)

The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
por: El, Kimberley, et al.
Publicado: (2023)

Fibroblast activation protein (FAP) as a novel metabolic target
por: Sánchez-Garrido, Miguel Angel, et al.
Publicado: (2016)

The Change in Glucagon Following Meal Ingestion Is Associated with Glycemic Control, but Not with Incretin, in People with Diabetes
por: Yoo, Soyeon, et al.
Publicado: (2021)

Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon
por: Kanasaki, Keizo, et al.
Publicado: (2019)

Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science
por: Singh, Awadhesh Kumar
Publicado: (2015)

Direct Control of Brown Adipose Tissue Thermogenesis by Central Nervous System Glucagon-Like Peptide-1 Receptor Signaling
por: Lockie, Sarah H., et al.
Publicado: (2012)

The Links of Ghrelin to Incretins, Insulin, Glucagon, and Leptin After Bariatric Surgery
por: Skuratovskaia, Daria, et al.
Publicado: (2021)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Subunit Vaccines Using TLR Triagonist Combination Adjuvants Provide Protection Against Coxiella burnetii While Minimizing Reactogenic Responses
por: Fratzke, Alycia P., et al.
Publicado: (2021)

Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus
por: Rauch, Thomas, et al.
Publicado: (2012)

A Facile Procedure for One-Pot Stable Conjugation of Two Proglucagon Cysteine-Containing Peptide Analogs
por: He, Rongjun, et al.
Publicado: (2021)

Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury
por: Bader, Miaad, et al.
Publicado: (2020)

Gαs regulates Glucagon-Like Peptide 1 Receptor-mediated cyclic AMP generation at Rab5 endosomal compartment
por: Girada, Shravan Babu, et al.
Publicado: (2017)

Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
por: Novikoff, Aaron, et al.
Publicado: (2021)

Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
por: Butler, Alexandra E., et al.
Publicado: (2013)

Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
por: Habegger, Kirk M., et al.
Publicado: (2013)

GIP: An Inconsequential Incretin or Not?
por: Pratley, Richard E.
Publicado: (2010)

“Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease
por: DiMarchi, Richard D.
Publicado: (2018)

Advances in the treatment of metabolic diseases
por: DiMarchi, Richard D.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vc2llgoucq7mjip9q8j8qtrlef